Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevelamer hydrochloride versus calcium carbonate for inflammatory markers in hemodialysis patients
IRCT20200724048193N1Phase 4Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Oct 2020
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in end-stage kidney disease (ESKD) comparing Sevelamer hydrochloride with Calcium carbonate (2 arms). Primary endpoints: Serum endotoxin level, Serum soluble CD14 level and 1 more. Started Oct 2020; status: completed.
02
Drugs
sevelamer carbonatecalcium carbonate
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on IRCT20200724048193N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200724048193N1.